Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

The Quick Take
LEXINGTON, Mass., Nov. 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its third quarter 2026...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Local
FOX NEWS MEDIA'S MULTIPLATFORM COVERAGE OF 2026 MIDTERM ELECTIONS DOMINATES CABLE NEWS DELIVERING NEARLY 4.7 MILLION VIEWERS
'FOX News Democracy 26' Tops CBS News, CNN, MS NOW in Primetime, with 'Evening News' Delivering Lowest Rated Midterm Coverage of the 21st Century FOX News…
Business
Pangaea earnings beat by $0.22, revenue topped estimates
Business
Analysis-Japanese savers have rediscovered interest rates and banks are feeling it
Business
